CAV1 and Miyoshi myopathy: Widely used and FDA‐approved cholesterol‐depleting drugs, lovastatin and simvastatin, have been proven to efficiently modulate CAV1 through the depletion of membrane cholesterol.[6, 13] We sought to determine whether they would reduce CAV1 in MM cells and benefit MM treatment.